Jan Lichtenberg's Biography

Jan Lichtenberg, CEO & Co-Founder, InSphero AG

Jan Lichtenberg, Ph.D., is Co-Founder and CEO of Swiss- and US-based InSphero Inc., the pioneer of industrial-grade, 3D-cell-based assay solutions and scaffold-free 3D organ-on-a-chip technology. Through partnerships, InSphero supports pharmaceutical and biotechnology researchers in successful decision-making by accurately rebuilding the human physiology in vitro. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and oncology (with a focus on immuno-oncology and PDX models). The scalable Akura™ technology underlying the company’s 3D InSight™ Discovery and Safety Platforms includes 96 and 384-well plate formats and the Akura™ Flow organ-on-a-chip system to drive efficient innovation throughout all phases of drug development. Jan co-founded InSphero in 2009 and expanded the business to encompass all top 15 global pharmaceutical companies. Prior to InSphero, Jan had VP R&D and Product Management positions at Hocoma AG (medical robotics) and Uwatec (microelectronics). He holds a Ph.D. from the University of Neuchâtel and managed a research group at the Swiss Federal Institute of Technology (ETH), Zurich.

Scaling 3D Assays From Discovery to Complex Mechanistic Multi-Tissue Experiments Using a Modular Microfluidic Platform

Friday, 5 October 2018 at 10:00

Add to Calendar ▼2018-10-05 10:00:002018-10-05 11:00:00Europe/LondonScaling 3D Assays From Discovery to Complex Mechanistic Multi-Tissue Experiments Using a Modular Microfluidic Platform3D-Culture and Organoids in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Multi-tissue devices, in which different biomimetic organ models can interact with each other, have the potential to prepone systemic biological investigations of compound action to the in vitro phase. Early systemic insight will have substantial impact on compound selection and the reduction of animal studies. Combining physiologically relevant organ models in perfusion systems bears technological challenges and often leads to complicated culturing setups. Complex systems limit assay robustness, reduce reproducibility and make integration into scalable, automated routine processes difficult. We present a new multi-tissue platform featuring microfluidic channels and chambers that were specifically engineered for culturing of microtissues and organoids under physiological flow conditions. The platform complies with the SBS plate standard and is made polystyrene to prevent unwanted compound absorption. Its concept allows for automated and on-demand interconnection of up to 10 microtissues per channel in a very flexible way. Multiple devices can be operated in parallel, which increases the number of conditions and statistical replicates that can be executed in parallel. With the broad range of available spheroid-based organ-models, a variety of pre-clinical testing applications can be served using the very same platform.

Add to Calendar ▼2018-10-04 00:00:002018-10-05 00:00:00Europe/London3D-Culture and Organoids3D-Culture and Organoids in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com

Corporate Sponsors

	3D-Culture, Organoids and Organs-on-Chips 2021 Location: Boston Date: 22/03/2021 - 23/03/2021

	Circulating Biomarkers 2021 Location: San Diego, California Date: 25/02/2021 - 26/02/2021

	The Space Summit 2021 Location: Boston Date: 24/05/2021 - 25/05/2021